Tags

Type your tag names separated by a space and hit enter

Uveitis following the BNT162b2 mRNA vaccination against SARS-CoV-2 infection: a possible association.
Retina. 2021 Aug 02 [Online ahead of print]R

Abstract

PURPOSE

To describe uveitis cases following the BNT162b2 mRNA SARS-CoV-2 vaccination.

METHODS

This is a multicenter, retrospective study. Vaccine related-uveitisdiagnosis was supported by the classification of the World Health Organization Adverse Drug Terminology and the Naranjo criteria.

RESULTS

Twenty-one patients (23 eyes) with a mean age of 51.3 years (23-78 years) were included. Eight /21 patients had a known history of uveitis, the median time from previous to current attack was 1 year (0.5-15 years). There were 21 anterior uveitis cases, two with bilateral inflammation. Eight cases occurred post first and 13 post second vaccination. All but 3 presented as mild to moderate disease. Two patients developed multiple evanescent white dot syndrome (MEWDS) following the second vaccination. Mean time between vaccination to uveitis onset was 7.5 ± 7.3 days (1-30 days). At final follow-up, complete resolution was achieved in all but two eyes, which showed significant improvement. One case of severe anterior uveitis developed vitritis and macular edema following second vaccination, which completely resolved following an intravitreal dexamethasone injection.

CONCLUSION

Uveitis may develop after the administration of the BNT162b2 mRNA vaccine. The most common complication was mild to moderate anterior uveitis, while less frequent, MEWDS can also occur.

Authors+Show Affiliations

Division of Ophthalmology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Israel Department of Ophthalmology, Rambam Medical Center, The Ruth and Bruce Rappaport Faculty of Medicine ,Technion, Israel Institute of Technology, Haifa, Israel Department of Ophthalmology, Galilee Medical Center, Bar Ilan University, Faculty of Medicine in the Galilee, Israel Department of Ophthalmology, Shaare Zedek Medical Center,Jerusalem Goldschleger Eye Institute, Department of Ophthalmology, Sheba Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Israel Department of Ophthalmology, Barzilai Medical Center, Ashkelon, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheba, Israel Department of Ophthalmology, Wolfson Medical Center, Holon, Sackler Faculty of Medicine, Tel Aviv University, Israel Department of Ophthalmology, Kaplan Medical Center, Rehovot, Faculty of Medicine, Hebrew University of Jerusalem, Israel.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

34369440

Citation

Rabinovitch, Tamar, et al. "Uveitis Following the BNT162b2 mRNA Vaccination Against SARS-CoV-2 Infection: a Possible Association." Retina (Philadelphia, Pa.), 2021.
Rabinovitch T, Ben-Arie-Weintrob Y, Hareuveni-Blum T, et al. Uveitis following the BNT162b2 mRNA vaccination against SARS-CoV-2 infection: a possible association. Retina. 2021.
Rabinovitch, T., Ben-Arie-Weintrob, Y., Hareuveni-Blum, T., Shaer, B., Vishnevskia-Dai, V., Shulman, S., Newman, H., Biadsy, M., Masarwa, D., Fischer, N., Yovel, O., Ben Zaken, S. G., & Habot-Wilner, Z. (2021). Uveitis following the BNT162b2 mRNA vaccination against SARS-CoV-2 infection: a possible association. Retina (Philadelphia, Pa.). https://doi.org/10.1097/IAE.0000000000003277
Rabinovitch T, et al. Uveitis Following the BNT162b2 mRNA Vaccination Against SARS-CoV-2 Infection: a Possible Association. Retina. 2021 Aug 2; PubMed PMID: 34369440.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Uveitis following the BNT162b2 mRNA vaccination against SARS-CoV-2 infection: a possible association. AU - Rabinovitch,Tamar, AU - Ben-Arie-Weintrob,Yael, AU - Hareuveni-Blum,Tamar, AU - Shaer,Boaz, AU - Vishnevskia-Dai,Vicktoria, AU - Shulman,Shiri, AU - Newman,Hadas, AU - Biadsy,Muhammad, AU - Masarwa,Dua, AU - Fischer,Naomi, AU - Yovel,Oren, AU - Ben Zaken,Shalhevet Goldfeather-, AU - Habot-Wilner,Zohar, Y1 - 2021/08/02/ PY - 2021/8/10/pubmed PY - 2021/8/10/medline PY - 2021/8/9/entrez JF - Retina (Philadelphia, Pa.) JO - Retina N2 - PURPOSE: To describe uveitis cases following the BNT162b2 mRNA SARS-CoV-2 vaccination. METHODS: This is a multicenter, retrospective study. Vaccine related-uveitisdiagnosis was supported by the classification of the World Health Organization Adverse Drug Terminology and the Naranjo criteria. RESULTS: Twenty-one patients (23 eyes) with a mean age of 51.3 years (23-78 years) were included. Eight /21 patients had a known history of uveitis, the median time from previous to current attack was 1 year (0.5-15 years). There were 21 anterior uveitis cases, two with bilateral inflammation. Eight cases occurred post first and 13 post second vaccination. All but 3 presented as mild to moderate disease. Two patients developed multiple evanescent white dot syndrome (MEWDS) following the second vaccination. Mean time between vaccination to uveitis onset was 7.5 ± 7.3 days (1-30 days). At final follow-up, complete resolution was achieved in all but two eyes, which showed significant improvement. One case of severe anterior uveitis developed vitritis and macular edema following second vaccination, which completely resolved following an intravitreal dexamethasone injection. CONCLUSION: Uveitis may develop after the administration of the BNT162b2 mRNA vaccine. The most common complication was mild to moderate anterior uveitis, while less frequent, MEWDS can also occur. SN - 1539-2864 UR - https://www.unboundmedicine.com/medline/citation/34369440/Uveitis_following_the_BNT162b2_mRNA_vaccination_against_SARS_CoV_2_infection:_a_possible_association_ L2 - https://doi.org/10.1097/IAE.0000000000003277 DB - PRIME DP - Unbound Medicine ER -